A study assessing the association of cyclin D1 and fulvestrant response in patients with hormone receptor-positive (HR+) breast cancer
Phase of Trial: Phase IV
Latest Information Update: 16 Jul 2015
At a glance
- Drugs Fulvestrant (Primary)
- Indications Breast cancer
- Focus Pharmacodynamics; Therapeutic Use
- 16 Jul 2015 New trial record
- 02 Jun 2015 Primary endpoint has been met (Duration of response and its relation with cyclin D1 expression), according to an abstract presented at the 51st Annual Meeting of the American Society of Clinical Oncology.
- 02 Jun 2015 Results presented at the 51st Annual Meeting of the American Society of Clinical Oncology.